1101 Westlake is BioMed’s second Seattle acquisition this quarter, increasing its existing portfolio and development pipeline to 2.6 million square feet in the region
April 29, 2022 02:09 PM Eastern Daylight Time
SEATTLE–(BUSINESS WIRE)–BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, today announced the acquisition of 1101 Westlake in Seattle. The 154,000-square-foot lab capable building, located in the premier South Lake Union neighborhood, is currently 100% leased to Meta.
“This acquisition marks an important milestone for BioMed’s growing Seattle portfolio while simultaneously highlighting the continued return to office of the technology industry”
The 1101 Westlake acquisition brings BioMed Realty’s portfolio of existing office and lab space in Seattle to 1.4 million square feet, which includes the flagship Dexter Yard project, located in close proximity to this new property. The company currently maintains a development pipeline of approximately 1.2 million square feet, which includes the recent Denny Park South acquisition and the T6 Innovation Center at 200 Taylor Avenue North.
“This acquisition marks an important milestone for BioMed’s growing Seattle portfolio while simultaneously highlighting the continued return to office of the technology industry,” said Jon Bergschneider, President of West Coast markets at BioMed Realty. “The acquisition of this prominent, 100% leased property will enable us to support the city’s innovation ecosystem and talent-rich community now and into the future.”
BioMed’s local tenants include industry leading life science and technology companies seeking to capitalize on the region’s talent, capital and research institutions, including the Seattle Children’s Hospital, Novo Nordisk Research Center Seattle, Inc., Omeros Corporation, InBios International, Inc., Lyell Immunopharma, Inc., Shape Therapeutics, Inc. and salesforce.com, inc. As BioMed bolsters its presence in the region, the Company will continue to prioritize its local community engagement initiatives, expanding on its ongoing efforts to create a more equitable, inclusive and climate-resilient Seattle.
Learn more about BioMed Realty’s Seattle properties, developments and operations here.
About BioMed Realty
BioMed Realty, a Blackstone portfolio company, is a leading provider of real estate solutions to the life science and technology industries. As of March 31, 2022, BioMed owns and operates high quality life science real estate comprising 14.9 million square feet concentrated in leading innovation markets throughout the United States and the United Kingdom, including Boston/Cambridge, San Francisco, San Diego, Seattle, Boulder and Cambridge, U.K. In addition, BioMed maintains a premier in process development platform with 4.6 million square feet of Class A properties in active construction and 5.6 million square feet of future development platforms in these core innovation markets to meet the growing demand of the life science and technology industries. To learn more about BioMed Realty, visit biomedrealty.com and follow the company on Twitter @biomedrealty.
Contacts
Media:
Maria Huntalas
Senior Director, Corporate Communications
858-207-5859
maria.huntalas@biomedrealty.com
The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE
